Methsuximide should not be used in patients with a history of hypersensitivity to succinimides.
Blood dyscrasias, including some with fatal outcome, have been reported to be associated with the use of succinimides; therefore, periodic blood counts should be performed.
- TRADE NAMES: Celontin (Pfizer); Petinutin
- INDICATIONS: Absence (petit-mal) seizures
- CLASS: Antiepileptic; succinimide
- HALF-LIFE: 2–4 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Phenobarbital, Phenytoin
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
